Remote Diabetic Foot Temperature Monitoring for Early Detection of Diabetic Foot Ulcers: A Cost-Effectiveness Analysis
Elizabeth Brooks,Megan Burns,Ran Ma,Henk Jan Scholten,Shawn Becker,Shawn H Becker
DOI: https://doi.org/10.2147/CEOR.S322424
2021-10-07
ClinicoEconomics and Outcomes Research
Abstract:Elizabeth Brooks, 1 Megan Burns, 1 Ran Ma, 2 Henk Jan Scholten, 2 Shawn Becker 3 1 TTi Health Research and Economics, Westminster, MD, USA; 2 Siren Care, Inc, San Francisco, CA, USA; 3 Silvercat Advisors, LLC, Burlingame, CA, USA Correspondence: Megan Burns TTi Health Research and Economics, 1231 Tech Ct Suite 201, Westminster, MD, 21157, USA Email Background: Foot temperature monitoring for the prevention and early detection of diabetic foot ulcers (DFU) is evidence-based and recommended in clinical practice. However, easy-to-use remote monitoring tools have been lacking, thereby preventing widespread adoption. Objective: To evaluate the cost-effectiveness of remote foot temperature monitoring (RFTM) (Siren's NeurofabricTM Diabetic socks) in addition to standard of care (SoC) versus SoC alone for early detection of DFU with diabetic neuropathy and a moderate to high risk of DFU. Methods: A payer perspective decision-tree analysis was conducted to compare expected DFU occurrence and subsequent amputation rates and costs between treatment strategies over one year. Inputs in the model were sourced from publicly available literature and relevant health technology assessments. One-way sensitivity analyses were performed for each model variable. Results: In the base-case scenario, RFTM plus SoC was a dominant strategy compared to SoC alone. RFTM plus SoC was associated with cost savings of 8027 per patient per year on average compared to SoC alone. These results were highly robust to one-way sensitivity analysis; all scenarios remained dominant if compliance was ≥ 13%. Conclusion: RFTM is a cost-effective addition to SoC in patients with diabetic neuropathy at a moderate-to-high risk of DFU and subsequent amputation. Further, reduction in DFU and associated complications may result in improvements in the patient's quality of life and mental health. Future studies are needed to evaluate the compliance and reduction of DFU occurrence in patients on RFTM. Keywords: diabetes mellitus, diabetic foot, technology assessment, biomedical, cost-benefit analysis, cost savings, decision trees Diabetes is a common and serious health issue in the United States (US), associated with a substantial clinical and economic burden. This burden is magnified when diabetes patients experience negative clinical consequences such as diabetic foot ulcers (DFU) and lower extremity amputation. As of 2015, 30 million US citizens had diabetes, accounting for 9% of the country's population. 1 Approximately 15–34% of people with diabetes are likely to experience DFU. 2,3 DFU is an open sore or wound on the foot of a diabetic patient, most commonly located on the bottom of the foot. 3 Diabetic patients at high risk for DFUs can include those with a history of DFUs, callus, or Charcot foot; such afflictions often lead to future ulceration. 4 Many ulcers heal with additional intervention; however, 14–24% of diabetes patients require amputation. In total, 85% of diabetes-related amputations are due to DFUs. 3 Patient outcomes and quality of life associated with both DFU and diabetes-related amputation are negative. Following a diabetes-related amputation, mortality exceeds 70% at 5 years for all patients. 2 Outcomes are poor for patients experiencing DFU; a recent study demonstrated that 1-, 2-, and 5-year survival rates with DFU were 81%, 69%, and 29% respectively. 5 Further, among those living with DFU, the incidence of concomitant depression is approximately 62%. 6 Only 25% to 50% of patients with diabetes who experience depression are clinically diagnosed and appropriately treated. 7 When such mental health issues go untreated, it can set off a cycle of worsening both the diabetic condition and the individual's depression. 7 Such issues may arise because worsened mental health may impact an individual's ability to stay compliant with diabetic treatment plans. 7 In addition, diabetes constitutes a substantial financial burden to the US healthcare system. In 2016, diabetes was found to be the third-highest cost in terms of US healthcare spending. 8 Annual direct costs for diabetes care in the US are upwards of 59 billion annually) is related to lower-extremity issues, including both DFU and diabetes-related amputations. 2 According to the American Diabetes Association, in 2018, diagnosis and management of diabetic foot complications cost the US approximately $43 billion. On a per-patient basis, treati -Abstract Truncated-